FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies
- 31 August 2002
- journal article
- clinical trial
- Published by Elsevier in Leukemia Research
- Vol. 26 (8) , 725-730
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Randomized clinical study comparing aggressive chemotherapy with or without G‐CSF support for high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDSBritish Journal of Haematology, 1998
- Fludarabine, cytarabine, G‐CSF and idarubicin (FLAG‐IDA) for the treatment of poor‐risk myelodysplastic syndromes and acute myeloid leukaemiaBritish Journal of Haematology, 1997
- Intensive Postremission Chemotherapy in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1994
- The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen‐year periodBritish Journal of Haematology, 1993
- Fludarabine and Arabinosylcytosine Therapy of Refractory and Relapsed Acute Myelogenous LeukemiaLeukemia & Lymphoma, 1993
- A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.Journal of Clinical Oncology, 1992
- Varying intensity of postremission therapy in acute myeloid leukemiaBlood, 1992
- Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemiaBlood, 1992
- Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemiaBlood, 1991
- Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.Journal of Clinical Oncology, 1988